Author

Rupali Roy

Observed names: R Roy, R. Roy

Institutions: Northwestern University, University of Michigan, Michigan Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Observed institutions: Northwestern University, University of Michigan, Michigan Medicine, Saroj Gupta Cancer Centre & Research Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University

OpenAlex ID: A5113586283

Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era

2013 · A.M. Evens, S. Choquet, et al. · American Journal of Transplantation · 189

Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression

2007 · A Sengupta, D Banerjee, et al. · Leukemia · 148

Post-Transplantation Lymphoproliferative Disorders: Diagnosis, Prognosis, and Current Approaches to Therapy

2010 · Andrew M. Evens, Rupali Roy, et al. · Current Oncology Reports · 141

β-Catenin Activates the HOXA10 and CDX4 Genes in Myeloid Progenitor Cells

2012 · Ling Bei, Chirag Shah, et al. · Journal of Biological Chemistry · 18

Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era

2013 · A. M. Evens, S. Choquet, et al. · American Journal of Transplantation · 16

Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation

2012 · Rupali Roy, Andrew M. Evens, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 15

Primary Central Nervous System (PCNS) Post-Transplant Lymphoproliferative Disease (PTLD): An International Report of 65 Cases in the Modern Era

2011 · Andrew M. Evens, Sylvain Choquet, et al. · Blood · 4

Bortezomib May Be Safely Combined with Y-90 Ibritumomab Tiuxetan In Patients with Relapsed/Refractory Follicular or Transformed Non-Hodgkin Lymphoma: A Phase I Trial of Combined Induction Therapy and Bortezomib Consolidation

2010 · Rupali Roy, Andrew M Evens, et al. · Blood · 2

Overcoming resistance in chronic myeloid leukemia

2013 · Rupali Roy, Moshe Talpaz · Clinical Investigation

Chemotherapy (Primary and Recurrent Disease)

2013 · Rupali Roy, Timothy M. Kuzel · Springer eBooks

Optimization of Postremission Therapy in Follicular Lymphoma: Efficacy of Rituximab Maintenance

2011 · Rupali Roy, Leo I. Gordon · Journal of the National Comprehensive Cancer Network

Works count: 11

Citation count: 533

H-index: 6

I10-index: 6